Ichnos Glenmark Innovation, Inc. (IGI), a global clinical-stage biotechnology company, has announced its latest development candidate, ISB 2301. This first-in-class, multispecific immune cells activator targets both T cells and natural killer (NK) cells for the potential treatment of multiple solid tumour indications. ISB 2301 is designed to engage three tumour-associated antigens, aiming to trigger tumour cell death and activate the immune system.
The development of ISB 2301 was facilitated by IGI’s clinically validated BEAT® platform, which enables the creation of complex multispecific antibodies. The candidate is advancing rapidly towards clinical trials, with IGI planning to submit an Investigational New Drug (IND) application by the end of the year, with clinical studies anticipated to commence in 2027.
Lida Pacaud, M.D., President and CEO of IGI, stated, “We engineered ISB 2301 to match the biological complexity of solid tumours in a way that conventional immunotherapies have not been able to address. By simultaneously targeting three tumour-associated antigens and engaging both T cells and NK cells, it deploys a level of multi-mechanistic precision that we believe sets a new benchmark for what multispecific antibodies can achieve in solid tumours.”
ISB 2301 is engineered to induce potent antibody-dependent cellular cytotoxicity (ADCC), potent checkpoint inhibition, and a sustained type 1 immune response. The candidate demonstrates excellent pharmacokinetics, tolerability, and a favourable safety profile in non-human primates.
The success of IGI’s prior lead investigational asset, ISB 2001, which attracted collaboration with AbbVie, underscores the potential of IGI’s platform. Pacaud noted, “It’s this same platform that provided the engineering capability to develop such a highly complex molecule as ISB 2301. We look forward to advancing ISB 2301 into clinical studies and exploring the potential of this novel therapeutic approach for cancer patients with solid tumours.”
IGI, headquartered in New York, is committed to developing innovative biologics in oncology, with a robust pipeline of novel, first-in-class Multispecifics™ aimed at addressing complex diseases. The company leverages its proprietary BEAT® technology platform to deliver breakthrough therapies for patients battling haematological malignancies and solid tumours.
Disclaimer: This article is based on a regulatory filing submitted to the National Stock Exchange of India (NSE).